Patent US4404366A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4404366A Expired / Lapsed US ⏱️ 0.0 years remaining

Beta-galactosyl-umbelliferone-labeled hapten conjugates

Assignee: Bayer Corp
•
Filing: 1981-07-16
•
Granted: 1983-09-13
•
Expires: 2001-07-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An improved specific binding assay method and reagent for determining a ligand in a liquid medium employing, as an enzyme-cleavable substrate label, a residue having the formula: G-D-R wherein G is a glycone, D is a dye indicator moiety, and R is a linking group through which the label residue is covalently bound to a binding component of a conventional binding assay system, such as the ligand, an analog thereof, or a specific binding partner thereof. The monitored characteristic of the label is the release of a detectable product, usually a fluorogen or chromogen, upon enzymatic cleavage of the glycosidic linkage between the glycone and the dye indicator moiety. The assay method may follow a homogeneous or heterogeneous format. The preferred glycone is a beta -galactosyl group and the preferred dye indicator moiety is an umbelliferone residue. The improved assay is particularly suited to the determination of haptens, such as drugs, and antigenic proteins and polypeptides, including antibodies, following a homogeneous competitive binding assay format.

Inventors

  • 👤 Robert C. Boguslaski
  • 👤 John F. Burd
  • 👤 Robert J. Carrico

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 07:35
CPC Classifications
C; C07; C07H; C07H17/00; C07H17/04; C07H17/06; C07H17/065; C07H17/075; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; G01N33/532; G01N33/533; G01N33/535

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 10 words
A β-galactosyl-umbelliferone-labeled theophylline conjugate of the formula: ##STR25## wherein n=2-6.
Claim 2
Dependent Claim 10 words
A β-galactosyl-umbelliferone-labeled theophylline conjugate of the formula: ##STR25## wherein n=2-6.
Claim 3
Dependent Claim 7 words
The conjugate of claim 1 wherein n=3.
Claim 4
Dependent Claim 14 words
A β-galactosyl-umbelliferone-labeled phenobarbital conjugate of the formula: ##STR26## wherein φ is phenyl and n=2-6.
Claim 5
Dependent Claim 14 words
A β-galactosyl-umbelliferone-labeled phenobarbital conjugate of the formula: ##STR26## wherein φ is phenyl and n=2-6.
Claim 6
Dependent Claim 7 words
The conjugate of claim 3 wherein n=4.
Claim 7
Dependent Claim 10 words
A β-galactosyl-umbelliferone-labeled carbamazepine conjugate of the formula: ##STR27## wherein n=2-6.
Claim 8
Dependent Claim 10 words
A β-galactosyl-umbelliferone-labeled carbamazepine conjugate of the formula: ##STR27## wherein n=2-6.
Claim 9
Dependent Claim 7 words
The conjugate of claim 5 wherein n=4.
Claim 10
Dependent Claim 14 words
A β-galactosyl-umbelliferone-labeled primidone conjugate of the formula: ##STR28## wherein φ is phenyl and n=2-6.
Claim 11
Dependent Claim 14 words
A β-galactosyl-umbelliferone-labeled primidone conjugate of the formula: ##STR28## wherein φ is phenyl and n=2-6.
Claim 12
Dependent Claim 7 words
The conjugate of claim 7 wherein n=4.
Claim 13
Dependent Claim 26 words
A β-galactosyl-umbelliferone-labeled hapten conjugate of the formula: ##STR29## wherein R is a linking group and L is a hapten of molecular weight between 100 and 1000.
Claim 14
Dependent Claim 26 words
A β-galactosyl-umbelliferone-labeled hapten conjugate of the formula: ##STR29## wherein R is a linking group and L is a hapten of molecular weight between 100 and 1000.
Claim 15
Dependent Claim 30 words
The conjugate of claim 9 wherein said linking group is a chain containing between 1 to 10 carbon atoms and 0 to 5 heteroatoms selected from nitrogen, oxygen and sulfur.
Claim 16
Dependent Claim 36 words
The conjugate of claim 9 wherein said hapten is selected from the group consisting of, diphenylhydantoin, phenobarbital, primidone, carbamazepine, ethosuximide, sodium valproate, theophylline, quinidine, procainamide, thyroxine, liothyronine, estriol, morphine, the barbiturates, the amphetamines, librium and valium.

References Cited (Backward Citations)

US4226978A Cited
US4279992A Cited
US4331590A Cited
US4259233A Cited
US4292425A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1986-09-12 1987-03-14 1987-09-13 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1990-09-12 1991-03-14 1991-09-13 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1994-09-12 1995-03-14 1995-09-13 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag